Emily Dayana Guzmán Ramos’s scientific contributions

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (2)


Diagnostic value of cardiac troponin tnt in acute myocardial infarction
  • Article
  • Full-text available

December 2024

·

6 Reads

Patricio Damián Mayorga Medina

·

Emily Dayana Guzmán Ramos

·

Francisco Xavier Poveda Paredes

·

María Augusta Reyes Pérez

The purpose of this study was to analyze whether troponin TnT is an effective marker for identifying acute myocardial infarction (AMI). A descriptive observational study was developed based on a literature review, addressing risk factors such as age, obesity, diabetes and smoking. The process of AMI and the role of troponins in the detection and prevention of cardiac damage were also explained. Methodological tools such as PICOT and PRISMA were used to select articles that evaluated the sensitivity of troponin TnT. The results indicated a sensitivity of 48.5% and a specificity of 48.2%, concluding that it is not a sensitive marker for the early diagnosis of AMI

Download

Psychiatric alterations associated with huntington's disease

December 2024

·

4 Reads

This study analyzes the psychiatric symptoms related to Huntington's disease, seeking a better understanding of its manifestations from a clinical-psychiatric approach. Through a descriptive study, data were collected from various sources, such as databases, scientific journals and specialized books. Huntington's disease is an autosomal dominant genetic disorder caused by CAG trinucleotide repeats in the HTT gene. Symptoms vary from case to case, usually appearing between the ages of 30 and 50, although it can manifest in adolescence as juvenile Huntington's disease. With motor and psychiatric manifestations, the diagnosis combines clinical, molecular and transcranial ultrasound evaluations. Currently, treatment is palliative, focused on mitigating symptoms